How is the liver primed or sensitized for alcoholic liver disease?
This article represents the proceedings of a symposium at the 2000 ISBRA Meeting in Yokohama, Japan. The chairs were Hidekazu Tsukamoto and Yoshiyuki Takei. The presentations were (1) Tribute to Professor Rajendar K. Chawla, by Craig J. McClain; (2) Dysregulated TNF signaling in alcoholic liver disease, by Craig J. McClain, S. Joshi-Barve, D. Hill, J Schmidt, I. Deaciuc, and S. Barve; (3) The role of mitochondria in ethanol-mediated sensitization of the liver, by Anna Colell, Carmen Garcia-Ruiz, Neil Kaplowitz, and Jose C. Fernandez-Checa; (4) A peroxisome proliferator (bezafibrate) can prevent superoxide anion release into hepatic sinusoid after acute ethanol administration, by Hirokazu Yokoyama, Yukishige Okamura, Yuji Nakamura, and Hiromasa Ishii; (5) S-adenosylmethionine affects tumor necrosis factor-alpha gene expression in macrophages, by Rajendar K. Chawla, S. Barve, S. Joshi-Barve, W. Watson, W. Nelson, and C. McClain; (6) Iron, retinoic acid and hepatic macrophage TNFalpha gene expression in ALD, by Hidekazu Tsukamoto, Min Lin, Mitsuru Ohata, and Kenta Motomura; and (7) Role of Kupffer cells and gut-derived endotoxin in alcoholic liver injury, by N. Enomoto, K. Ikejima, T. Kitamura, H. Oide, Y. Takei, M. Hirose, B. U. Bradford, C. A. Rivera, H. Kono, S. Peter, S. Yamashina, A. Konno, M. Ishikawa, H. Shimizu, N. Sato, and R. Thurman.
Tsukamoto
H
H
USC-UCLA Research Center for Alcoholic Liver and Pancreatic Diseases, Los Angeles, California 90033-1034, USA. htsukamo@hsc.usc.edu
Takei
Y
Y
McClain
C J
CJ
Joshi-Barve
S
S
Hill
D
D
Schmidt
J
J
Deaciuc
I
I
Barve
S
S
Colell
A
A
Garcia-Ruiz
C
C
Kaplowitz
N
N
Fernandez-Checa
J C
JC
Yokoyama
H
H
Okamura
Y
Y
Nakamura
Y
Y
Ishii
H
H
Chawla
R K
RK
Barve
S
S
Joshi-Barve
S
S
Watson
W
W
Nelson
W
W
Lin
M
M
Ohata
M
M
Motomura
K
K
Enomoto
N
N
Ikejima
K
K
Kitamura
T
T
Oide
H
H
Hirose
M
M
Bradford
B U
BU
Rivera
C A
CA
Kono
H
H
Peter
S
S
Yamashina
S
S
Konno
A
A
Ishikawa
M
M
Shimizu
H
H
Sato
N
N
Thurman
R
R
D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology; D004731:Endotoxins / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects / Q000502:physiology*; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007501:Iron / Q000378:metabolism; D007728:Kupffer Cells / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008108:Liver Diseases, Alcoholic / Q000209:etiology* / Q000378:metabolism; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000378:metabolism; D020025:Peroxisome Proliferators / Q000494:pharmacology; D012436:S-Adenosylmethionine / Q000378:metabolism; D013481:Superoxides / Q000378:metabolism*; D014212:Tretinoin / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D004731:Endotoxins; D000960:Hypolipidemic Agents; D020025:Peroxisome Proliferators; D014409:Tumor Necrosis Factor-alpha; D013481:Superoxides; D014212:Tretinoin; D012436:S-Adenosylmethionine; D007501:Iron; D001629:Bezafibrate